Current Rheumatology Reports

, Volume 12, Issue 4, pp 237–249 | Cite as

Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues

  • Sergio M. A. Toloza
  • Meenakshi Jolly
  • Graciela S. Alarcón


Although the survival rate for systemic lupus erythematosus (SLE) has improved dramatically during the past 50 years, the quality of life of patients afflicted with this disease remains poor. Currently existent measures of disease activity and damage in SLE do not capture the patient’s perspective and health-related quality of life (HRQoL). Most studies in SLE pertaining to HRQoL are from developed Western societies, with only a few from others. These studies have been conducted predominantly in women and using the Medical Outcomes Survey Short Form 36, a generic HRQoL instrument that has been shown not to be sensitive to change in lupus. Existent lupus-specific HRQoL measures have not yet been used in SLE clinical trials. New HRQoL research tools are currently undergoing validation in different countries, languages, and cultural settings, which may help dissect the underlying role of socioeconomic status and specific disease-related features that impact SLE-related quality of life.


Systemic lupus erythematosus Health-related quality of life Quality of life Cross-cultural issues Lupus 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989, 32:1107–1118.CrossRefPubMedGoogle Scholar
  2. 2.
    Bombardier C, Gladman DD, Urowitz MB, et al.: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630–640.CrossRefPubMedGoogle Scholar
  3. 3.
    Symmons DP, Coppock JS, Bacon PA, et al.: Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988, 69:927–937.PubMedGoogle Scholar
  4. 4.
    Gladman DD, Urowitz MB, Goldsmith CH, et al.: The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:809–813.CrossRefPubMedGoogle Scholar
  5. 5.
    Strand V, Gladman D, Isenberg D, et al.: Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus 2000, 9:322–327.CrossRefPubMedGoogle Scholar
  6. 6.
    Siegel JN: Development of an FDA guidance document for clinical trials in SLE. Lupus 1999, 8:581–585.CrossRefPubMedGoogle Scholar
  7. 7.
    McHorney CA, Ware JE Jr, Raczek AE: The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31:247–263.CrossRefPubMedGoogle Scholar
  8. 8.
    •• Thumboo J, Strand V: Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore 2007, 36:115–122. This is an interesting review of the literature on HRQoL and of the measures on how to improve it in patients with SLE.PubMedGoogle Scholar
  9. 9.
    Alarcón GS, McGwin G Jr, Uribe A, et al.: Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 2004, 51:465–474.CrossRefPubMedGoogle Scholar
  10. 10.
    Gladman DD, Urowitz MB, Ong A, et al.: A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 1996, 5:190–195.CrossRefPubMedGoogle Scholar
  11. 11.
    Gladman DD, Urowitz MB, Ong A, et al.: Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol 1996, 14:305–308.PubMedGoogle Scholar
  12. 12.
    Jolly M: How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005, 32:1706–1708.PubMedGoogle Scholar
  13. 13.
    Jolly M, Utset TO: Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus 2004, 13:924–926.CrossRefPubMedGoogle Scholar
  14. 14.
    •• Aggarwal R, Wilke CT, Pickard AS, et al.: Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol 2009, 36:1209–1216. The psychometric properties of two preference-based generic HRQoL measures, the EQ-5D and SF-6D, among US patients with SLE were assessed and found to be satisfactory. Measures of disease activity and damage were found to be weakly correlated with HRQoL.CrossRefPubMedGoogle Scholar
  15. 15.
    Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 1998, 28:551–558.CrossRefGoogle Scholar
  16. 16.
    Milligan SE, Hom DL, Ballou SP, et al.: An assessment of the Health Assessment Questionnaire functional ability index among women with systemic lupus erythematosus. J Rheumatol 1993, 20:972–976.PubMedGoogle Scholar
  17. 17.
    Burckhardt CS, Archenholtz B, Bjelle A: Quality of life of women with systemic lupus erythematosus: a comparison with women with rheumatoid arthritis. J Rheumatol 1993, 20:977–981.PubMedGoogle Scholar
  18. 18.
    Lash AA: Quality of life in systemic lupus erythematosus. Appl Nurs Res 1998, 11:130–137.CrossRefPubMedGoogle Scholar
  19. 19.
    Archenholtz B, Burckhardt CS, Segesten K: Quality of life of women with systemic lupus erythematosus or rheumatoid arthritis: domains of importance and dissatisfaction. Qual Life Res 1999, 8:411–416.CrossRefPubMedGoogle Scholar
  20. 20.
    Leong KP, Kong KO, Thong BY, et al.: Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQoL). Rheumatology (Oxford) 2005, 44:1267–1276.CrossRefGoogle Scholar
  21. 21.
    • Doward LC, McKenna SP, Whalley D, et al.: The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis 2009, 68:196–200. The development and testing of a new instrument to measure QoL (L-QoL) in 93 adult SLE patients from the United Kingdom is described.CrossRefPubMedGoogle Scholar
  22. 22.
    • McElhone K, Abbott J, Shelmerdine J, et al.: Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. Arthritis Rheum 2007, 57:972–979. The development and validation process of a self-report (patient-derived items) lupus-specific measure (LupusQoL) in a predominantly female and Caucasian SLE population from the United Kingdom is described.CrossRefPubMedGoogle Scholar
  23. 23.
    •• Jolly M, Pickard AS, Wilke C, et al.: Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis 2010, 69:29–33. The first SLE-specific HRQoL instrument modified and validated for use in an ethnically diverse US population is described. Satisfactory psychometric properties are presented.CrossRefPubMedGoogle Scholar
  24. 24.
    • Jolly M, Pickard AS, Fogg L, et al.: US patient derived lupus-specific patient reported outcome measure (Lupus-PRO©): validity and reliability. Arthritis Rheum 2008, 58(9 S):S805. The validity and reliability of the LupusPRO in an ethnically heterogeneous US population are presented.Google Scholar
  25. 25.
    Yu EB, Shikiar R, Howard K, et al.: Validation of LUP-QOL: a lupus-specific measure of health-related quality of life (HRQL) [abstract 0499]. Ann Rheum Dis 2006, 65(Suppl II).Google Scholar
  26. 26.
    •• Moorthy LN, Peterson MG, Baratelli M, et al.: Multicenter validation of a new quality of life measure in pediatric lupus. Arthritis Rheum 2007, 57:1165–1173. The development and validation of SMILEY as a brief, easily understood, valid, and reliable pediatric, SLE-specific QoL scale are described.CrossRefPubMedGoogle Scholar
  27. 27.
    Moorthy LN, Peterson MG, Baratelli MJ, et al.: Preliminary cross-cultural adaptation of a new pediatric health-related quality of life scale in children with systemic lupus erythematosus: an international effort. Lupus 2010, 19:83–88.CrossRefPubMedGoogle Scholar
  28. 28.
    Beaton DE, Bombardier C, Guillemin F, Ferraz MB: Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000, 25:3186–3191.Google Scholar
  29. 29.
    •• Colangelo KJ, Pope JE, Peschken C: The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. J Rheumatol 2009, 36:2231–2237. This was a Canadian study addressing the concept of the minimally important difference in patients with SLE. This minimally important difference may differ bidirectionally depending on the measured outcome (specific values for the MCS and PCS scores of the SF-36 are provided).CrossRefPubMedGoogle Scholar
  30. 30.
    Kong KO, Ho HJ, Howe HS, et al.: Cross-cultural adaptation of the Systemic Lupus Erythematosus Quality of Life Questionnaire into Chinese. Arthritis Rheum 2007, 57:980–985.CrossRefPubMedGoogle Scholar
  31. 31.
    Jolly M, Pickard AS, Wilke C, et al.: Development and validation of a US lupus specific patient reported outcome measure. Arthritis Rheum 2007, 56(9 S):S113.Google Scholar
  32. 32.
    Bastian HM, Roseman JM, McGwin G Jr, et al.: Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002, 11:152–160.CrossRefPubMedGoogle Scholar
  33. 33.
    • Durán S, Apte M, Alarcón GS; LUMINA Study Group: poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. J Natl Med Assoc 2007, 99:1196–1198. This carefully written review emphasizes the role of poor SES (poverty) in the increased mortality rates observed in patients with SLE.PubMedGoogle Scholar
  34. 34.
    •• Kuriya B, Gladman DD, Ibañez D, Urowitz MB: Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008, 59:181–185. In this study, SF-36 scores changed little over time (during an 8-year period); these changes were not affected by disease activity, glucocorticoid exposure, or accrued damage but were affected by the concomitant presence of fibromyalgia.CrossRefPubMedGoogle Scholar
  35. 35.
    Clarke AE, Panopalis P, Petri M, et al.: SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 2008, 47:329–333.CrossRefGoogle Scholar
  36. 36.
    •• Appenzeller S, Clarke AE, Panopalis P, et al.: The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol 2009, 36:947–952. SLE patients with active renal disease had a slightly poorer QoL (physical subscales) than those without renal disease; however, it was not possible to accurately estimate whether a longitudinal change in renal disease activity was associated with a change in QoL.CrossRefPubMedGoogle Scholar
  37. 37.
    • Mok CC, Ho LY, Cheung MY, et al.: Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009, 38:121–127. This study evaluated and demonstrated the effects of persistent active disease and previous and new damage on the deterioration of SF-36 scores.CrossRefPubMedGoogle Scholar
  38. 38.
    • Dua A, Kamen DL, Barnado AL, et al.: Variable health-related quality of life among African American cohorts of patients with systemic lupus erythematosus. Arthritis Rheum 2009, 60(10 S):S112. This was a comparative study of demographic and HRQoL variables in two African American SLE patient groups of different genetic admixtures and geographic locations (urban and rural). Significantly worse HRQoL was found among the urban African Americans than among their rural counterparts.Google Scholar
  39. 39.
    •• Sanchez ML, McGwin G Jr, Durán S, et al.: Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): use of the SF-6D. Clin Exp Rheumatol 2009, 27:67–71. The SF-6D utility measure was used in this multiethnic study. Hispanic-Texan ethnicity and higher levels of social support were found to be positive predictors of HRQoL, whereas sociodemographic (older age, poverty) and disease-related (greater disease activity and damage, higher levels of fatigue, helplessness, and abnormal illness-related behaviors) variables were found to be negative predictors; prior SF-6D was found to be the strongest predictor of subsequent HRQoL.PubMedGoogle Scholar
  40. 40.
    •• Fernández M, Alarcón GS, McGwin G Jr, et al.: Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort. Arthritis Rheum 2007, 57:986–992. In this multiethnic SLE cohort, the SF-6D was found to be associated with damage accrual, but not with mortality. CrossRefPubMedGoogle Scholar
  41. 41.
    Freire E, Bruscato A, Ciconelli R: Quality of life in systemic lupus erythematosus patients in northeastern Brazil: is health-related quality of life a predictor of survival for these patients? Acta Reumatol Port 2009, 34:207–211.PubMedGoogle Scholar
  42. 42.
    •• Wolfe F, Michaud K, Li T, Katz RS: EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol 2010, 37:296–304. This was a large comparison study of the EQ-5D and SF-36 (1316 SLE patients vs 13,722 rheumatoid arthritis, 3623 with noninflammatory rheumatic disorders, and 2733 with fibromyalgia). No differences in the EQ-5D and PCS scores among patients with these diseases were found. The MCS of the SF-36 was found to be lower in SLE than in rheumatoid arthritis and noninflammatory rheumatic disorders; poor QoL in SLE was predicted by disease damage and the number of comorbid events.CrossRefPubMedGoogle Scholar
  43. 43.
    Khanna S, Pal H, Pandey RM, Handa R: The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology (Oxford) 2004, 43:1536–1540.CrossRefGoogle Scholar
  44. 44.
    Klein R, Moghadam-Ki S, LoMonico J, et al.: Quality of life in cutaneous lupus erythematosus. Arthritis Rheum 2009, 60(10 S):S107.Google Scholar
  45. 45.
    Jolly M, Pickard AS, Mikolaitis R, et al.: Disease activity, body image and health status in Lupus. Arthritis Rheum 2007, 56:S454.Google Scholar
  46. 46.
    Grootscholten C, Ligtenberg G, Derksen RH, et al.: Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Qual Life Res 2003, 12:635–644.CrossRefPubMedGoogle Scholar
  47. 47.
    •• Grootscholten C, Snoek FJ, Bijl M, et al.: Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/methylprednisolone in a randomized controlled trial. J Rheumatol 2007, 34:1699–1707. This small study compared the treatment effect of cyclophosphamide pulses plus oral prednisone versus azathioprine combined with intravenous methylprednisolone during a 24-month period on HRQoL in 87 predominantly Caucasian patients with proliferative LN. The study showed that aggressive treatment with immunosuppressive drugs and concomitant glucocorticoids improves HRQoL, especially in the first year.PubMedGoogle Scholar
  48. 48.
    •• Dussán KB, Magder L, Brodsky RA, et al.: High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus 2008, 17:1079–1085. In this small randomized controlled trial, high-dose cyclophosphamide was compared with monthly intravenous cyclophosphamide in first-time cyclophosphamide users. Improvement in several components of the SF-36 was demonstrated at 6 months in the high-dose cyclophosphamide patient group, but equal improvement in the two arms was demonstrated at 36 months.CrossRefPubMedGoogle Scholar
  49. 49.
    Medeiros MM, Menezes AP, Silveira VA, et al.: Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med 2008, 19:122–128.CrossRefPubMedGoogle Scholar
  50. 50.
    Uppal SS, Hayat SJ, Raghupathy R: Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009, 18:690–697.CrossRefPubMedGoogle Scholar
  51. 51.
    •• Jolly M, Sandler D, Sequeira W, et al.: Hydroxy-chloroquine use and disease specific health related quality of life in systemic lupus erythematosus. Arthritis Rheum 2009, 60(10 S):S108. The beneficial effects of hydroxychloroquine in preventing major lupus flares, retarding damage accrual, and improving patient survival are well-known; however, no demonstrable effect of hydroxychloroquine on the LupusQoL-US or the LupusPRO could be demonstrated in this study.Google Scholar
  52. 52.
    Alarcón GS, McGwin G, Bertoli AM, et al.: Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort. Ann Rheum Dis 2007, 66:1168–1172.CrossRefPubMedGoogle Scholar
  53. 53.
    Ito H, Matsuno T, Hirayama T, et al.: Health-related quality of life in patients with systemic lupus erythematosus after medium to long-term follow-up of hip arthroplasty. Lupus 2007, 16:318–323.CrossRefPubMedGoogle Scholar
  54. 54.
    Alvarez-Nemegyei J, Bautista-Botello A, Dávila-Velázquez J: Association of complementary or alternative medicine use with quality of life, functional status or cumulated damage in chronic rheumatic diseases. Clin Rheumatol 2009, 28:547–551.CrossRefPubMedGoogle Scholar
  55. 55.
    Karlson EW, Liang MH, Eaton H, et al.: A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum 2004, 50:1832–1841.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Sergio M. A. Toloza
    • 1
  • Meenakshi Jolly
    • 2
  • Graciela S. Alarcón
    • 3
  1. 1.Hospital San Juan BautistaCatamarcaArgentina
  2. 2.Division of RheumatologyRush University Medical CenterChicagoUSA
  3. 3.Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations